Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Amortization - Intangibles (2016 - 2025)

Vanda Pharmaceuticals' Amortization - Intangibles history spans 16 years, with the latest figure at $1.8 million for Q4 2025.

  • On a quarterly basis, Amortization - Intangibles fell 1.18% to $1.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.1 million, a 3.25% decrease, with the full-year FY2025 number at $7.0 million, down 3.66% from a year prior.
  • Amortization - Intangibles hit $1.8 million in Q4 2025 for Vanda Pharmaceuticals, roughly flat from $1.8 million in the prior quarter.
  • Over the last five years, Amortization - Intangibles for VNDA hit a ceiling of $2.0 million in Q1 2024 and a floor of $369000.0 in Q4 2021.
  • Historically, Amortization - Intangibles has averaged $987550.0 across 5 years, with a median of $408000.0 in 2021.
  • Biggest five-year swings in Amortization - Intangibles: surged 404.5% in 2024 and later fell 10.8% in 2025.
  • Tracing VNDA's Amortization - Intangibles over 5 years: stood at $369000.0 in 2021, then increased by 12.74% to $416000.0 in 2022, then soared by 137.98% to $990000.0 in 2023, then soared by 79.09% to $1.8 million in 2024, then dropped by 1.18% to $1.8 million in 2025.
  • Business Quant data shows Amortization - Intangibles for VNDA at $1.8 million in Q4 2025, $1.8 million in Q3 2025, and $1.8 million in Q2 2025.